Hayek Kallen Investment Management Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

Hayek Kallen Investment Management increased its stake in Pfizer Inc. (NYSE:PFE) by 1.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 98,437 shares of the biopharmaceutical company’s stock after buying an additional 1,179 shares during the period. Pfizer accounts for about 2.2% of Hayek Kallen Investment Management’s holdings, making the stock its 18th largest holding. Hayek Kallen Investment Management’s holdings in Pfizer were worth $3,537,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of PFE. Bath Savings Trust Co raised its stake in Pfizer by 3.4% during the second quarter. Bath Savings Trust Co now owns 17,217 shares of the biopharmaceutical company’s stock worth $746,000 after acquiring an additional 564 shares in the last quarter. Cox Capital Mgt LLC increased its stake in shares of Pfizer by 1.5% in the second quarter. Cox Capital Mgt LLC now owns 37,986 shares of the biopharmaceutical company’s stock valued at $1,646,000 after buying an additional 565 shares during the period. Thomasville National Bank increased its stake in shares of Pfizer by 4.1% in the second quarter. Thomasville National Bank now owns 76,628 shares of the biopharmaceutical company’s stock valued at $3,319,000 after buying an additional 3,001 shares during the period. Park National Corp OH increased its stake in shares of Pfizer by 27.6% in the second quarter. Park National Corp OH now owns 252,546 shares of the biopharmaceutical company’s stock valued at $10,941,000 after buying an additional 54,642 shares during the period. Finally, Deane Retirement Strategies Inc. increased its stake in shares of Pfizer by 1.8% in the second quarter. Deane Retirement Strategies Inc. now owns 51,699 shares of the biopharmaceutical company’s stock valued at $2,240,000 after buying an additional 894 shares during the period. Institutional investors own 71.52% of the company’s stock.

In other news, Director Scott Gottlieb bought 3,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were bought at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the acquisition, the director now directly owns 3,000 shares in the company, valued at $104,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

NYSE:PFE traded up $0.14 on Friday, reaching $37.05. 24,924,227 shares of the stock traded hands, compared to its average volume of 23,366,957. The firm has a market capitalization of $207.30 billion, a price-to-earnings ratio of 12.35, a price-to-earnings-growth ratio of 2.11 and a beta of 0.67. The company’s 50 day moving average is $36.62 and its 200-day moving average is $39.26. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 1-year low of $33.97 and a 1-year high of $46.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.13. The business had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The company’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.78 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is 48.00%.

PFE has been the subject of several recent research reports. DZ Bank raised Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective for the company in a research note on Wednesday, August 28th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. UBS Group reaffirmed a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a research note on Monday, August 5th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Finally, Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a research note on Tuesday, October 1st. Nine analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $44.02.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: How to find the components of the quick ratio

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.